Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

VentriPoint Diagnostics Ltd V.VPT

Alternate Symbol(s):  VPTDF

Ventripoint Diagnostics Ltd. is a Canada-based medical device company. It is engaged in the development and commercialization of diagnostic tools to monitor patients with heart disease. It develops a suite of applications for all heart diseases and imaging modalities, including congenital heart disease, pregnancy, pulmonary hypertension, COVID-19, technically difficult imaging and cardiotoxicity in oncology patients. It provides application of artificial intelligence to echocardiography. Its flagship product, Ventripoint Medical System (VMS+), enhances echocardiography to deliver cMRI levels of accuracy for volumetric measurements and ejection fractions for all four chambers of the heart. It has developed a solution that transforms cardiac care through its 3D ECHO and MRI software. VMS products are powered by its proprietary Knowledge Based Reconstruction technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI.


TSXV:VPT - Post by User

Bullboard Posts
Post by wanttoretireearlyon Mar 04, 2017 10:55am
239 Views
Post# 25931425

Production of VMS Plus underway since Oct. 2016

Production of VMS Plus underway since Oct. 2016
This if from October 2016 NR:

"We are now starting the process to transfer the manufacturing knowledge for the VMS-PLUS to the facility in Ma'anshan by sending all the components necessary to build the first batch of VMS-PLUS machines and our staff to train the operators in China," stated Dr. George Adams, CEO of Ventripoint. "This has been a long time coming and we are pleased to announce that accessing the market in China is finally on its way. I look forward to updating our shareholder over the coming months."

This is a major milestone as the opportunity in China continues to expand and we feel with manufacturing now beginning, the Company is in a position to drive tremendous value for our shareholders in the quarters to come. The first machines are expected to be constructed by the end of the year (2016) and will be used to facilitate the submission to the Chinese FDA for marketing approval, as well as to demonstrate the machine to distributors in China. Our Chinese partners are establishing a distribution network for all of China.

Ventripoint retains the rights to market all its products including those further developed in China for the rest of the world.


Read more at https://www.stockhouse.com/news/press-releases/2016/10/31/ventripoint-receives-first-order-for-vms-plus-components-from-china-and-applies#Kp0YPR8oOdlPsgTg.99
Bullboard Posts